Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009
Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009
复制标题
DOI：
10.1016/j.ijantimicag.2011.04.022
复制
发表时间：
2011-10-01
影响因子：
10.8
通讯作者：
Bordon, Jose M.
中科院分区：
文献类型：
--
作者：
Master, Ronald N.;Clark, Richard B.;Bordon, Jose M.
铜绿假单胞菌是一种医院和社区获得性病原体，与相当大的患者发病率和死亡率相关。铜绿假单胞菌的多药耐药性是一个令人担忧的问题，因为可用于治疗该微生物引起的感染的治疗选择有限。在这项研究中，铜绿假单胞菌分离株的抗菌药物耐药率监测网络数据库-美国（Eurofins Medinet，Chantilly，VA）从1997年至2009年进行了检查。根据患者背景和年龄以及标本来源对患者人群和标本进行分层。多重耐药定义为对以下三种或三种以上抗菌药物的耐药性：氨曲南;头孢吡肟;环丙沙星;亚胺培南;庆大霉素;和哌拉西林/他唑巴坦（TZP）。本研究共检测了924 740株铜绿假单胞菌。对单个抗菌药物的耐药率变化如下：
Pseudomonas aeruginosa is a nosocomial and community-acquired pathogen associated with considerable patient morbidity and mortality. Multidrug resistance in P. aeruginosa is a concern owing to the limited therapeutic options available to treat infections due to this organism. In this study, rates of antimicrobial resistance of P. aeruginosa isolates collected by The Surveillance Network Database-USA (Eurofins Medinet, Chantilly, VA) from 1997 to 2009 were examined. The patient population and specimens were stratified according to patient setting and age as well as specimen source. Multidrug resistance was defined as resistance to three or more of the following antimicrobial agents: aztreonam; cefepime; ciprofloxacin; imipenem; gentamicin; and piperacillin/tazobactam (TZP). A total of 924 740 P. aeruginosa isolates were examined in this study. Changes in resistance rates to individual antimicrobial agents were